Novo Nordisk shares fall on pricing, M&A uncertainty despite 2030 pipeline target

Novo Nordisk shares declined as investors weigh pricing pressure on Wegovy and uncertainty over M&A strategy, despite management's announcement of plans to launch over five blockbuster drugs by 2030 and generate more than 150 billion Danish kroner. The market reaction suggests skepticism about the achievability of these targets amid competitive and regulatory headwinds. This matters as Novo Nordisk is a bellwether for the GLP-1 drug market, with implications for healthcare sector sentiment.